2. Iakovou, I., et al., Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005. 293(17): p. 2126-30.
3. Schatz, R.A., et al., Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation, 1991. 83(1): p. 148-61.
7. Ong, A.T., et al., Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol, 2005. 45(6): p. 947-53.
9. Moses, J.W., et al., Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003. 349(14): p. 1315-23.
11. De la Torre-Hernandez, J.M., et al., Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol, 2008. 51(10): p. 986-90.
12. Daemen, J., et al., Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007. 369(9562): p. 667-78.
15. Steinhubl, S.R., et al., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002. 288(19): p. 2411-20.
18. Mehran, R., et al., Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, 2013. 382(9906): p. 1714-22.
19. Brar, S.S., et al., Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol, 2011. 58(19): p. 1945-54.
20. Price, M.J., et al., Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011. 305(11): p. 1097-105.
21. Wiviott, S.d., et al., Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J, 2006. 152(4): p. 627-35.
22. Preobrazhenskii, d.v., [Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study]. Kardiologiia, 2010. 50(1): p. 68.
26.
23. Steg, P.G., et al., Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation, 2013. 128(10): p. 1055-65.
24. Gurbel, P.A., et al., Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET study. Circulation, 2009. 120(25): p. 2577-85.